Search

Displaying results 571 - 580 of 10000 in total
  1. Drug

    Nintedanib

    go.drugbank.com/drugs/DB09079
    ApprovedInvestigational

    [L8453,L8459] It was first approved for use in the United States in 2014. … Nintedanib is a small molecule kinase inhibitor used in the treatment of pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease, and non-small cell lung cancer (NSCLC).

    Products: NINTEDANIB EG
  2. Drug

    Cyclobenzaprine

    go.drugbank.com/drugs/DB00924
    ApprovedInvestigational

    Cyclobenzaprine, a centrally-acting muscle relaxant, was first synthesized in 1961[A185039] and has been available for human use since 1977. … [A185039,A184982] Since its approval, it has remained relatively popular as an adjunctive, short-term treatment for acute skeletal muscle spasms secondary to musculoskeletal injury.

    Mixtures: RODALGIN COMPLEX TABLETASSynonyms: N,N-dimethyl-5H-dibenzo(a,d)cycloheptene-Δ5,γ-propylamine
  3. Drug

    Flecainide

    go.drugbank.com/drugs/DB01195
    ApprovedInvestigationalWithdrawn

    [A186880] Flecainide’s development began in 1966 and was first synthesized in 1972 as an attempt to generate new anesthetics. … [L8878,L5056] Flecainide was granted FDA approval on 31 October 1985.[L8875]

    Synonyms: N-(2-Piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamideProducts: FLECAINIDE EG
  4. Drug

    Propafenone

    go.drugbank.com/drugs/DB01182
    ApprovedInvestigational

    An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity. The drug is generally well tolerated.

    Products: PROPAFENONE EG
  5. Drug

    Darifenacin

    go.drugbank.com/drugs/DB00496
    ApprovedInvestigational

    This block reduces the urgency to urinate and so it should not be used in people with urinary retention. … It is unknown if M3 receptor selectivity is clinically advantageous in overactive bladder syndrome treatments.

    Products: DARUCIL® ER 15 MG
  6. Drug

    Deferasirox

    go.drugbank.com/drugs/DB01609
    ApprovedInvestigational

    Deferasirox is an iron chelator and the first oral medication FDA approved for chronic iron overload in patients receiving long term blood transfusions.

    Categories: Compounds used in a research, industrial, or household settingProducts: DEFERASIROX EG, DEFERASIROX SUN
  7. Drug

    Baclofen

    go.drugbank.com/drugs/DB00181
    ApprovedInvestigational

    Although originally designed in 1962 to treat epilepsy, baclofen was not effective in treating this condition but instead was shown to reduce spasticity in selected patients. … [A245338] Baclofen was reintroduced in 1971 as a treatment for spasticity and was later approved by the FDA in 1977.

    Products: BACLOFENE SUN, OREN FORTE TABLETAS
  8. Drug

    Colchicine

    go.drugbank.com/drugs/DB01394
    ApprovedInvestigational

    [L47591] It has also been investigated in other inflammatory and fibrotic conditions.[A183602] … Colchicine is an alkaloid drug derived from a plant belonging to the Lily family, known as _Colchicum autumnale_, or "autumn crocus."[A183611] Its use was first approved by the FDA in 1961.

    Categories: Preparations With No Effect on Uric Acid MetabolismProducts: PMS-colchicine ER
  9. Drug

    Mometasone

    go.drugbank.com/drugs/DB00764
    ApprovedInvestigational

    Mometasone is a corticosteroid not currently used in medical products. [Mometasone furoate] however, is still in use.

    Products: MOMETASONE EG
  10. Drug

    Gefitinib

    go.drugbank.com/drugs/DB00317
    ApprovedInvestigational

    Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa. … Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer.

    Synonyms: N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamineProducts: GEFITINIB EG